First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients. Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged in the past two decades, underscoring the need for innovative research and new treatments that can improve both survival and quality of life for patients and their families.
- Ponto de atenção: first.
- Ponto de atenção: human.
- Ponto de atenção: immunotherapy.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
